Post-licensure safety evaluation of dihydroartemisinin piperaquine in the three major ecological zones across Ghana.

ABSTRACT:

Background

Uncommon and rare adverse events (AEs), with delayed onset may not be detected before new drugs are licensed and deployed. The present study examined the post licensure safety of dihydroartemisinin-piperaquine (DHP) as an additional treatment for malaria in Ghana. The relationship between the incidence of AEs, treatment completion rate, participant characteristics and concomitant medications are reported.

Methods

A study conducted from September 2013 to June 2014 in Navrongo, Kintampo and Dodowa health research centres in Ghana is presented. Participants had confirmed malaria and no known allergy to study drug. Patients provided informed consent and had their symptoms and results of their clinical examinations documented. Treatment with Eurartesim® (20/160mg dihyd

SUBMITTER: Oduro AR 

PROVIDER: S-EPMC5373525 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature